Abstract
Background: Drug induced bile duct injury is a frequently observed clinical problem leading to a wide range of pathological features. During the past decades, several agents have been identified with various postulated mechanisms of bile duct damage, however, mostly still poorly understood. Methods: Here, we investigated the mechanisms of chlorpromazine (CPZ) induced bile duct injury using advanced in vitro cholangiocyte cultures. Intrahepatic cholangiocyte organoids (ICOs) were driven into mature cholangiocyte like cells (CLCs), which were exposed to CPZ under cholestatic or non-cholestatic conditions through the addition of a bile acid cocktail. Results: CPZ caused loss of monolayer integrity by reducing expression levels of tight junction protein 1 (TJP1), E-cadherin 1 (CDH1) and lysyl oxidase homolog 2 (LOXL2). Loss of zonula occuludens-1 (ZO-1) and E-cadherin was confirmed by immunostaining after exposure to CPZ and rhodamine-123 leakage further confirmed disruption of the cholangiocyte barrier function. Furthermore, oxidative stress seemed to play a major role in the early damage response by CPZ. The drug also decreased expression of three main basolateral bile acid transporters, ABCC3 (ATP binding cassette subfamily C member 3), SLC51A/B (solute carrier family 51 subunit alpha/beta) and multidrug resistance transporter ABCB1 (ATP binding cassette subfamily B member 1), thereby contributing to bile acid accumulation. CPZ did not induce an inflammatory response by itself, but addition of TNFα revealed a synergistic effect. Conclusion: These results show that ICOs present a model to identify toxic drugs affecting the bile ducts while providing mechanistic insights into hepatotoxicity.
| Original language | English |
|---|---|
| Article number | 78 |
| Pages (from-to) | 1-15 |
| Number of pages | 15 |
| Journal | Stem cell research & therapy |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 13 Mar 2024 |
Bibliographical note
Publisher Copyright:© The Author(s) 2024.
Funding
This work was supported by the China Scholarship Council (No. 201808620130) and by the PPP Allowance made available by Health ~ Holland, Top Sector Life Sciences & Health, to the Association of Collaborating Health Foundations (SGF) to stimulate public–private partnerships (LSHM20045-SGF). LJWL and MMV gratefully acknowledges funding from NWO ENW-XS Open Competition Grant (Project OCENW.XS21.2.003), the Medical Delta (Regenerative Medicine 4D program) and the Convergence Health Technology Flagship grant “Organ Transplantation” of the Erasmus MC and TU Delft.
| Funders | Funder number |
|---|---|
| Medical Delta | |
| Erasmus Medisch Centrum | |
| Health ~ Holland, Top Sector Life Sciences & Health | |
| Technische Universiteit Delft | |
| Collaborating Health Foundations | |
| China Scholarship Council | 201808620130 |
| St.George Foundation | LSHM20045-SGF |
| Nederlandse Organisatie voor Wetenschappelijk Onderzoek | OCENW.XS21.2.003 |
Keywords
- Advanced in vitro model
- Barrier disruption
- Bile acid
- Chlorpromazine
- Cholangiocytes
- Drug induced bile duct injury
- Intrahepatic cholangiocyte organoids
- Transporter